KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Common Equity (2016 - 2025)

Amgen has reported Common Equity over the past 17 years, most recently at $8.7 billion for Q4 2025.

  • Quarterly results put Common Equity at $8.7 billion for Q4 2025, up 47.32% from a year ago — trailing twelve months through Dec 2025 was $8.7 billion (up 47.32% YoY), and the annual figure for FY2025 was $8.7 billion, up 47.32%.
  • Common Equity for Q4 2025 was $8.7 billion at Amgen, down from $9.6 billion in the prior quarter.
  • Over the last five years, Common Equity for AMGN hit a ceiling of $9.6 billion in Q3 2025 and a floor of $916.0 million in Q1 2022.
  • Median Common Equity over the past 5 years was $6.5 billion (2021), compared with a mean of $6.3 billion.
  • Biggest five-year swings in Common Equity: tumbled 90.19% in 2022 and later surged 483.84% in 2023.
  • Amgen's Common Equity stood at $6.7 billion in 2021, then crashed by 45.36% to $3.7 billion in 2022, then skyrocketed by 70.23% to $6.2 billion in 2023, then fell by 5.7% to $5.9 billion in 2024, then skyrocketed by 47.32% to $8.7 billion in 2025.
  • The last three reported values for Common Equity were $8.7 billion (Q4 2025), $9.6 billion (Q3 2025), and $7.4 billion (Q2 2025) per Business Quant data.